Table of Contents
Leukemia Research and Treatment
Volume 2014, Article ID 143479, 12 pages
http://dx.doi.org/10.1155/2014/143479
Research Article

In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells

1Department of Clinical Science, Hematology Section, University of Bergen, 5021 Bergen, Norway
2Department of Molecular Biosciences, University of Oslo, 0316 Oslo, Norway
3Department of Biomedicine, University of Bergen, Norway
4Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway

Received 28 July 2013; Accepted 28 October 2013; Published 8 January 2014

Academic Editor: Judith E. Karp

Copyright © 2014 Hilde Kvestad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. L. Doan and J. P. Chute, “The vascular niche: home for normal and malignant hematopoietic stem cells,” Leukemia, vol. 26, no. 1, pp. 54–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. B. S. Guerrouahen, I. Al-Hijji, and A. R. Tabrizi, “Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia,” Stem Cells International, Article ID 375857, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. Ø. Bruserud, C. Stapnes, E. Ersvær, B. T. Gjertsen, and A. Ryningen, “Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells,” Current Pharmaceutical Biotechnology, vol. 8, no. 6, pp. 388–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Döhner, E. H. Estey, S. Amadori et al., “Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet,” Blood, vol. 115, no. 3, pp. 453–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Estey, “AML in older patients: are we making progress?” Best Practice and Research: Clinical Haematology, vol. 22, no. 4, pp. 529–536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Fredly, H. Reikvam, B. T. Gjertsen, and Ø. Bruserud, “Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment,” American Journal of Hematology, vol. 87, no. 4, pp. 368–376, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kuendgen, M. Schmid, R. Schlenk et al., “The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia,” Cancer, vol. 106, no. 1, pp. 112–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Raffoux, P. Chaibi, H. Dombret, and L. Degos, “Treatment of elderly acute myeloid leukemia with valproic acid and all-trans retinoic acid,” Haematologica, vol. 90, no. 7, pp. 986–988, 2005. View at Google Scholar · View at Scopus
  9. E. Raffoux, A. Cras, C. Recher et al., “Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome,” Oncotarget, vol. 1, no. 1, pp. 34–42, 2010. View at Google Scholar · View at Scopus
  10. C. Stapnes, A. Ryningen, B. T. Gjertsen, and Ø. Bruserud, “Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia,” Acta Oncologica, vol. 45, no. 3, pp. 346–349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. Ø. Bruserud, C. Stapnes, K. J. Tronstad, A. Ryningen, N. Ånensen, and B. T. Gjertsen, “Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML,” Expert Opinion on Therapeutic Targets, vol. 10, no. 1, pp. 51–68, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Fredly, C. Stapnes Bjørnsen, B. T. Gjertsen, and Ø. Bruserud, “Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia—a report of five cases,” Hematology, vol. 15, no. 5, pp. 338–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Fredly, B. T. Gjertsen, and O. Bruserud, “Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents,” Clinical Epigenetics, vol. 5, p. 12, 2013. View at Google Scholar
  14. A. O. Soriano, H. Yang, S. Faderl et al., “Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome,” Blood, vol. 110, no. 7, pp. 2302–2308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Gurvich, O. M. Tsygankova, J. L. Meinkoth, and P. S. Klein, “Histone deacetylase is a target of valproic acid-mediated cellular differentiation,” Cancer Research, vol. 64, no. 3, pp. 1079–1086, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Stapnes, A. Ryningen, K. Hatfield et al., “Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors,” International Journal of Oncology, vol. 31, no. 6, pp. 1529–1538, 2007. View at Google Scholar · View at Scopus
  17. A. Ryningen, C. Stapnes, K. Paulsen, P. Lassalle, B. T. Gjertsen, and Ø. Bruserud, “In vivo biological effects of ATRA in the treatment of AML,” Expert Opinion on Investigational Drugs, vol. 17, no. 11, pp. 1623–1633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Brown and P. Hughes, “Retinoid differentiation therapy for common types of acute myeloid leukemia,” Leukemia Research and Treatment, vol. 2012, Article ID 939021, 11 pages, 2012. View at Publisher · View at Google Scholar
  19. I. Hubeek, G.-J. L. Kaspers, G. J. Ossenkoppele, and G. J. Peters, “Deoxynucleoside analogs in cancer therapy,” in Cancer Drug Discovery and Development, G. J. Peters, Ed., pp. 119–152, 2006. View at Google Scholar
  20. Ø. Bruserud, A. Ryningen, L. Wergeland, N. I. Glenjen, and B. T. Gjertsen, “Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts,” Haematologica, vol. 89, no. 4, pp. 391–402, 2004. View at Google Scholar · View at Scopus
  21. K. Hatfield, A. M. Øyan, E. Ersvaer et al., “Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators,” British Journal of Haematology, vol. 144, no. 1, pp. 53–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Glenjen, E. Ersvæ, A. Ryningen, and Ø. Bruserud, “In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts,” International Journal of Cancer, vol. 111, no. 6, pp. 858–867, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Reikvam, I. Nepstad, O. Bruserud, and K. J. Hatfield, “Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells,” Oncotarget, vol. 4, pp. 830–843, 2013. View at Google Scholar
  24. K. Hatfield, A. Ryningen, M. Corbascio, and Ø. Bruserud, “Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts,” International Journal of Cancer, vol. 119, no. 10, pp. 2313–2321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. Ø. Bruserud, K. J. Tronstad, and R. Berge, “In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum,” Journal of Cancer Research and Clinical Oncology, vol. 131, no. 6, pp. 377–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Rochet, P. Leroy, D. F. Far, L. Ollier, A. Loubat, and B. Rossi, “CAL72: a human osteosarcoma cell line with unique effects on hematopoietic cells,” European Journal of Haematology, vol. 70, no. 1, pp. 43–52, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Evensen, D. R. Micklem, A. Blois et al., “Mural cell associated VEGF is required for organotypic vessel formation,” PLoS ONE, vol. 4, no. 6, Article ID e5798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Evensen, D. R. Micklem, W. Link, and J. B. Lorens, “A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery,” Cytometry Part A, vol. 77, no. 1, pp. 41–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. K. J. Hatfield, L. Evensen, H. Reikvam, J. B. Lorens, and O. Bruserud, “Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks,” European Journal of Haematology, vol. 89, pp. 478–490, 2012. View at Google Scholar
  30. H. Ishikura, H. Sawada, and T. Okazaki, “The effect of a low dose Ara-C in acute non-lymphoblastic leukaemias and atypical leukaemia,” British Journal of Haematology, vol. 58, no. 1, pp. 9–18, 1984. View at Google Scholar · View at Scopus
  31. T. Padró, S. Ruiz, R. Bieker et al., “Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia,” Blood, vol. 95, no. 8, pp. 2637–2644, 2000. View at Google Scholar · View at Scopus
  32. K. J. Hatfield, A. M. Olsnes, B. T. Gjertsen, and Ø. Bruserud, “Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies,” Current Cancer Drug Targets, vol. 5, no. 4, pp. 229–248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. Ø. Bruserud, A. Ryningen, A. M. Olsnes et al., “Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells,” Haematologica, vol. 92, no. 3, pp. 332–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Butler, H. Kobayashi, and S. Rafii, “Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors,” Nature Reviews Cancer, vol. 10, no. 2, pp. 138–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Ding, T. L. Saunders, G. Enikolopov, and S. J. Morrison, “Endothelial and perivascular cells maintain haematopoietic stem cells,” Nature, vol. 481, no. 7382, pp. 457–462, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Blum, R. B. Klisovic, B. Hackanson et al., “Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3884–3891, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Fredly, E. Ersvaer, A. O. Kittang, G. Tsykunova, B. T. Gjertsen, and O. Bruserud, “The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia,” Clinical Epigenetics, vol. 5, p. 13, 2013. View at Google Scholar
  38. A. Ryningen, C. Stapnes, P. Lassalle, M. Corbascio, B.-T. Gjertsen, and Ø. Bruserud, “A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid,” Leukemia Research, vol. 33, no. 6, pp. 779–787, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Muindi, S. R. Frankel, W. H. Miller Jr. et al., “Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid ”resistance” in patients with acute promyelocytic leukemia,” Blood, vol. 79, no. 2, pp. 299–303, 1992. View at Google Scholar · View at Scopus
  40. P. C. Adamson, “All-trans-retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia,” Oncologist, vol. 1, no. 5, pp. 305–314, 1996. View at Google Scholar · View at Scopus
  41. T. R. Breitman, S. E. Selonick, and S. J. Collins, “Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 5 I, pp. 2936–2940, 1980. View at Google Scholar · View at Scopus
  42. W. Hiddemann, “Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens,” Annals of Hematology, vol. 62, no. 4, pp. 119–128, 1991. View at Google Scholar · View at Scopus
  43. A. P. Periclou and V. I. Avramis, “NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias,” Cancer Chemotherapy and Pharmacology, vol. 39, no. 1-2, pp. 42–50, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. J. O. Liliemark, C. Y. Paul, C. G. Gahrton, and C. O. Peterson, “Pharmacokinetics of 1-β-D-arabinofuranosylcytosine 5-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-β-D-arabinofuranosylcytosine,” Cancer Research, vol. 45, no. 5, pp. 2373–2375, 1985. View at Google Scholar · View at Scopus
  45. M. Michaelis, U. R. Michaelis, I. Fleming et al., “Valproic acid inhibits angiogenesis in vitro and in vivo,” Molecular Pharmacology, vol. 65, no. 3, pp. 520–527, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. A. M. Roy, K. N. Tiwari, W. B. Parker, J. A. Secrist III, R. Li, and Z. Qu, “Antiangiogenic activity of 4′-thio-β-D-arabinofuranosylcytosine,” Molecular Cancer Therapeutics, vol. 5, no. 9, pp. 2218–2224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. T. L. Riss and R. A. Moravec, “Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays,” Assay and Drug Development Technologies, vol. 2, no. 1, pp. 51–62, 2004. View at Google Scholar · View at Scopus
  48. A. R. Kini, L. C. Peterson, M. S. Tallman, and M. W. Lingen, “Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid,” Blood, vol. 97, no. 12, pp. 3919–3924, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Saito, A. Sugawara, A. Uruno et al., “All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling,” Endocrinology, vol. 148, no. 3, pp. 1412–1423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. E. S. Arsenou, E. P. Papadimitriou, E. Kliafa, M. Hountala, and S. S. Nikolaropoulos, “Effects of retinoic acid steroidal analogs on human leukemic HL60 cell proliferation in vitro and on angiogenesis in vivo,” Anti-Cancer Drugs, vol. 16, no. 2, pp. 151–158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Ellis, H. Hammers, and R. Pili, “Targeting tumor angiogenesis with histone deacetylase inhibitors,” Cancer Letters, vol. 280, no. 2, pp. 145–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Zhang, L.-P. Song, Y. Huang, Q. Zhao, K.-W. Zhao, and G.-Q. Chen, “Accumulation of hypoxia-inducible factor-1α protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid,” Haematologica, vol. 93, no. 10, pp. 1480–1487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Dutta, T. Sen, A. Banerji, S. Das, and A. Chatterjee, “Studies on multifunctional effect of all-trans retinoic acid (ATRA) on matrix metalloproteinase-2 (MMP-2) and its regulatory molecules in human breast cancer cells (MCF-7),” Journal of Oncology, vol. 2009, Article ID 627840, 13 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Engl, I. Natsheh, I. Müller, W.-D. Beecken, D. Jonas, and R. A. Blaheta, “Valproic acid induces expression of neutrophil chemoattractants of the CXC chemokine family in endothelial cells,” International Journal of Clinical Pharmacology and Therapeutics, vol. 42, no. 10, pp. 568–574, 2004. View at Google Scholar · View at Scopus
  55. M. Michaelis, T. Suhan, U. R. Michaelis et al., “Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells,” Cell Death and Differentiation, vol. 13, no. 3, pp. 446–453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Tang, A.-M. Faussat, P. Majdak et al., “Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1,” Leukemia, vol. 18, no. 7, pp. 1246–1251, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. R. H. Stauber, S. K. Knauer, N. Habtemichael et al., “A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer,” Oncotarget, vol. 3, pp. 31–43, 2012. View at Google Scholar